Alexion doles out $22M upfront for two preclinical RNAi drugs from Dicerna
Former biotech ace Alexion Pharmaceuticals is still shopping to fatten its pipeline as it continues to shake off a sales practices scandal linked to its expensive rare disease drug Soliris that culminated in an executive exodus and top-to-bottom reorganization. On Wednesday, the Boston, MA-based company said it would fork out $22 million upfront to co-develop two preclinical RNAi therapies owned by Dicerna Pharmaceuticals $DRNA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.